Autosomal dominant polycystic kidney disease (ADPKD), the most commonly inherited kidney disease, is characterized by the development of cysts in the kidney that impair function. Of those affected, half will progress to end-stage kidney disease by age 60, requiring dialysis or kidney transplant. To date, no effective and safe therapies exist for this deadly disease. Tolvaptan (Tol), the only FDA-approved drug for treatment of ADPKD, has some benefit in slowing kidney disease progression, but Tol causes frequent urination and thirst and also injures the liver in a small number of patients. The investigators' goal, therefore, is to develop new strategies to treat ADPKD that are safe and tolerable.
The development of cysts in ADPKD patients results from two main cellular processes. The first is cell growth with an increase in the number of kidney cells that make up the outer surface of the cyst. The second is an increase in fluid secretion into the cysts that develop. The investigators have shown that an enzyme, AMP-activated protein kinase (AMPK), when activated can inhibit both of those processes. Moreover, genetic mutations that cause ADPKD may alter the energy metabolism of the cell, which in turn inhibits AMPK activity. Bempedoic acid (BA), a medication that is FDA-approved for the treatment of individuals with high cholesterol and has a good safety record, activates AMPK. In addition to activating AMPK, BA inhibits a second enzyme called ATP-citrate lyase (ACLY), which is involved in cholesterol synthesis. ACLY has received growing attention as a novel target for cancer treatment. ACLY inhibition blocks increases of cell numbers by inhibiting the lipid synthesis that is required for creation of new cell membranes. This study will test whether targeting these pathways through treatment with BA will help reverse dysfunctional metabolism in individuals with ADPKD and slow disease progression.
The investigators will test this using a phase 2 clinical trial in which 120 individuals with rapidly progressive ADPKD and an estimated glomerular filtration rate of 35 or greater will be treated with either BA or placebo (inactive look-alike pill) for two years. Participants on or off a stable dose of Tol will be included in the study. Participants will be recruited from the U. of Vermont, U. of Maryland, and Tufts University, which have active PKD clinics and are recognized by the PKD Foundation as Centers of Excellence. Through follow-up visits and lab work, the investigators will assess the safety and tolerability of BA in the participants as the primary outcomes. The secondary goals are to assess preliminary efficacy and effects of BA on quality of life in study participants. The growth of cysts results in increased volume or size of the kidneys and liver. Total and cyst volumes of the kidney and liver and visceral abdominal fat content via magnetic resonance imaging (MRI) will be measured to gauge the effectiveness of this drug. The investigators also predict that proteins and small molecules involved in regulating cell energy metabolism, inflammation, and injury, as well as proteins directly involved in AMPK and ACLY function, will be altered in ADPKD patients. Levels of these proteins and small molecules may then subsequently change with BA therapy. Exploratory, mechanistic goals of this study are to identify prognostic and predictive urinary biomarkers in study participants. Successful completion of this study would have a significant impact on individuals with ADPKD by laying the groundwork for a new treatment strategy as well as by providing a new way to help guide treatment decisions.
In summary, the goals of this phase 2 randomized, double-blind, placebo-controlled clinical trial are to test the safety, tolerability and preliminary efficacy of the drug bempedoic acid, FDA-approved to lower cholesterol, when used in ADPKD patients.

Start Date01 Feb 2026

Sponsor / Collaborator

University of Vermont

[+5]

ChiCTR2600119506

/ Not yet recruitingNot ApplicableIIT

A Real-World Study on the Efficacy and Safety of Ezetimibe Combined with Rosuvastatin in the Treatment of Elderly Patients with ASCVD

Start Date01 Feb 2026

Sponsor / Collaborator-

CTIS2025-521086-28-00

/ Not yet recruitingPhase 4IIT

Randomized clinical trial to assess the efficacy and safety of a strategy for primary prevention of cardiovascular disease in patients with inflammatory rheumatic diseases based on the use of carotid ultrasound.

Start Date01 Jan 2026

Sponsor / Collaborator-

100 Clinical Results associated with Bempedoic acid

100 Translational Medicine associated with Bempedoic acid

100 Patents (Medical) associated with Bempedoic acid

153

Literatures (Medical) associated with Bempedoic acid

01 Mar 2026·Atherosclerosis plus

LDL-C lowering in patients treated with bempedoic acid in a real-world cohort

Article

Author: Nelson, James ; Lewandowski, Dave ; Bloedon, LeAnne ; Ajose, Maryam ; Sarnes, Evelyn ; Vaduganathan, Muthiah ; Bonafede, Mac

Background:

Elevated low-density lipoprotein cholesterol (LDL-C) is directly associated with cardiovascular disease, with the risk level determined by the magnitude and duration of exposure. In routine practice, there are limited data on the expected LDL-C lowering with bempedoic acid (BA) alone or in combination with ezetimibe (BA + EZE).

Methods:

Patients initiating BA or BA + EZE were identified in the Veradigm Network EHR linked to claims (index). LDL-C levels were evaluated at baseline, 3, 6, and 12 months. To further examine BA and BA + EZE efficacy, patients were stratified by background statin use (12 months pre-index) and by continuous index therapy use (no therapy gap >45 days).

Results:

Of the 900 BA and 615 BA + EZE patients identified, median baseline LDL-C was 137 mg/dL and 127 mg/dL, respectively. By 3 months, BA (21%) and BA + EZE (33%, p < 0.0001 for both) were associated with significant reductions in median LDL-C levels. At baseline, only 6.3% of BA and 8.5% of BA + EZE patients had LDL-C <70 mg/dL; by 3 months, this increased to 16.8% and 33.3%. Over 12 months, 18.0% and 27.5% of patients had LDL-C <70 mg/dL. When stratified, the median reductions by 3 months highlighted use of BA and BA + EZE in patients without background statin use (BA: 24.2%; BA + EZE: 36.7%) and with continuous use (BA: 26.1%; BA + EZE: 40.2%).

Conclusions:

Patients initiating BA and BA + EZE experienced early and sustained LDL-C improvements. The greatest reductions were in patients with continuous use and patients with no evidence of prior statin use, underscoring the importance of long-term adherence and treating patients not on statin therapy.

01 Feb 2026·MOLECULAR THERAPY

High-capacity adenoviral vector-mediated expression of an LDLR/transferrin chimeric protein in muscle reduces atherosclerosis in Ldlr−/− mice

Article

Author: Pagliaro, Raffaella ; Coluccino, Ludovica ; Tripodi, Lorella ; Castaldo, Giuseppe ; Pastore, Lucio ; Cerullo, Vincenzo ; Vitale, Maria ; Bianco, Andrea ; D'Agostino, Anna ; Scialò, Filippo

Familial hypercholesterolemia (FH) is a genetic disorder caused by mutations in the low-density lipoprotein (LDL) receptor, leading to impaired uptake of LDL and its accumulation in arterial walls and other tissues. This accumulation results in cardiovascular disease and early mortality. Treatments, including statins, ezetimibe, PCSK9 inhibitors, and bempedoic acid, are often insufficient in homozygous FH patients, particularly those with null mutations in the LDL receptor (LDLR). To address this unmet need, we have developed two helper-dependent adenoviral (HD-Ad) vectors for the expression of the murine and human versions of a protein composed of the extracellular portion of the LDLR fused to transferrin. In both cassettes, expression is driven by the murine creatine kinase promoter to obtain high levels of expression restricted to muscle cells, to mitigate host response to the fusion protein. Both human and murine proteins restored LDL uptake in Ldlrf-deficient cells, correcting the phenotype in vitro. A single intramuscular administration of the HD-Ad vector induced the expression of the murine fusion protein, leading to a 12-month improvement in the lipid profile, with a reduction in aortic atherosclerosis in Ldlr-deficient mice. Furthermore, we observed no major systemic toxicity, indicating that the present strategy may represent more effective therapy for FH patients.

01 Feb 2026·AMERICAN HEART JOURNAL

Evolocumab before percutaneous coronary intervention for acute myocardial infarction: Design of the AMUNDSEN trial

Article

Author: Chioccioli, Marco ; Duband, Benjamin ; Montalescot, Gilles ; Ferrari, Emile ; Esposito, Giovanni ; Cequier-Fillat, Angel ; Guedeney, Paul ; Redjimi, Nassim ; Bartus, Stanislaw ; Mach, François ; Batias-Moreau, Laure ; Bouleti, Claire ; Vicaut, Eric ; Range, Grégoire ; Braik, Nassim ; Silvain, Johanne ; Brochard, Karine ; Picchi, Andréa ; Zeitouni, Michel ; Bolognese, Leonardo ; Souteyrand, Géraud ; Jukema, J Wouter ; Thiele, Holger

RATIONALE:

PCSK9 inhibitors are currently recommended as third-line therapy for post-myocardial infarction (MI) patients, added to high-dose statin, ezetimibe, and potentially bempedoic acid when the LDL-C target of <55 mg/dL is not achieved. These guideline-driven indications result in delayed initiation of PCSK9 inhibitors, potentially missing the opportunity for benefit during the acute phase. Recent studies have demonstrated that early PCSK9 inhibition promotes anti-inflammatory effects and plaque stabilization, suggesting a potential role early in MI management.

METHODS:

The AMUNDSEN trial is a randomized, international, phase IV study using a PROBE (Prospective Randomized Open, Blinded Endpoint) design to evaluate the effects of early PCSK9 inhibition in high-risk acute MI patients undergoing percutaneous coronary intervention (PCI). A total of 2,166 patients were enrolled, including those with ST-elevation MI undergoing primary PCI and those with non-ST-elevation MI with an indication for PCI, all presenting with at least 1 high-risk clinical characteristic. Patients were randomized to receive either immediate evolocumab prior to PCI alongside standard care or standard care alone. The primary objective is to achieve both a ≥ 50% reduction in LDL-C from baseline and a target LDL-C < 55 mg/dL at 12 months. The main clinical objective is to assess the composite of all-cause death or unplanned hospitalization for a cardiovascular (CV) reason at 12 months.

CURRENT STATUS:

Enrollment and randomization are complete. Lipid and clinical follow-up are ongoing. Results from this study will clarify the lipid-lowering efficacy and clinical impact of early evolocumab initiation in the acute MI setting.

CONCLUSION:

The AMUNDSEN trial will provide critical insights into the potential benefits of early PCSK9 inhibition in high-risk MI patients undergoing PCI.

CLINICAL TRIAL REGISTRATION:

NCT (clinicaltrials.gov): 04951856 - EUCT number: 2024-518195-31-00.

130

News (Medical) associated with Bempedoic acid

12 Mar 2026

·www.biospace.com

HLS Therapeutics Announces Fiscal 2025 Financial Results

Adjusted EBITDA 1 grew 18% to $19.6 million in fiscal 2025 Cash from operations grew 114% to $17.1 million in fiscal 2025 In-licensed NILEMDO ™ and NEXLIZET ® for the Canadian market; NILEMDO approved by Health Canada in November 2025 and is now commercially available Announced new credit facility with lower rates, increased flexibility and reduced F/X risk; reduced long term debt by 26%, achieving 43% reduction in annual interest expense TORONTO , March 12, 2026 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and twelve months ended December 31, 2025 ("Q4 2025" and "fiscal 2025"). All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated. Q4 & F2025 FINANCIAL HIGHLIGHTS (comparisons are to the respective 2024 periods) Fiscal 2025 revenue was $55.5 million, Adjusted EBITDA was $19.6 million and cash from operations was $17.1 million, compared to $56.6 million, $16.6 million and $8 million, respectively. Q4 2025 revenue was $15.2 million, Adjusted EBITDA was $5.7 million and cash from operations was $6.5 million, compared to $15.5 million, $5.6 million and $3.2 million, respectively. Canadian product sales increased 1.5% in fiscal 2025 in local currency and decreased 0.5% in Q4 2025. Foreign exchange negatively impacted fiscal 2025 reported revenue by approximately $0.8 million. U.S. Clozaril sales decreased 1.6% in fiscal 2025, an improvement from the prior four-year average annual decline of 6%, reflecting the success of the Company's specialty pharmacy program. Q4 2025 sales decreased 9% due primarily to timing of year-end customer shipments. Excluding cost of sales, operating expenses decreased 17% in fiscal 2025 and 6% in Q4 2025. For direct brand contribution to Adjusted EBITDA in fiscal 2025 - Clozaril contributed $26.9 million and Vascepa contributed $1 million, marking a pivot to full year profitability for Vascepa. Q4 & F2025 CORPORATE HIGHLIGHTS Expanded cardiovascular portfolio by licensing Canadian rights to NILEMDO ™ and NEXLIZET ® from Esperion Therapeutics. Received Health Canada approval for NILEMDO in Q4 2025 with product available as of March 2026. Made principal repayments on long-term debt totaling $17.8 million for fiscal 2025, including $5.0 million in Q4 2025. Secured new credit agreement with improved terms, helping to reduce fiscal 2025 interest expense by 43% compared to fiscal 2024. "In 2025, HLS made considerable progress against our objectives to drive profitable growth, strengthen our balance sheet, and lay the foundation for future growth," said Craig Millian, Chief Executive Officer at HLS. "We achieved 18% Adjusted EBITDA growth for the full year while generating $17.1 million in cash from operations, up 114% compared to 2024. Changes to our cardiovascular sales force are making an impact, with Vascepa unit growth of 23% for the year and strengthening new-to-brand momentum. We've de-levered our balance sheet, reduced our cost structure, and executed on our business plan. In 2026, we will leverage the efficiency and profitability gains we've made to advance towards our next stage of growth " "NILEMDO and NEXLIZET represent a significant opportunity. NILEMDO offers physicians and patients an effective, well-tolerated oral treatment option at a fraction of the cost of injectable alternatives. With an estimated 500,000 eligible patients in Canada and compelling data from the CLEAR Outcomes trial, we believe this franchise will more than double the size of our cardiovascular business. We were pleased to announce that NILEMDO is now available with a full commercial launch coming in early April." 2026 OUTLOOK 2026 financial targets are as follows: Consolidated revenue of $56-60 million, representing mid-single-digit percentage growth. Consolidated Adjusted EBITDA of $18.5-21 million, representing relatively flat year-over-year performance largely due to NILEMDO launch costs. Of note, future results could be impacted by continued exchange rate volatility. Mr. Millian added: "Our 2026 guidance reflects modest growth in our base business along with some increased investment to drive a successful NILEMDO launch. The real growth story accelerates beyond this year as NILEMDO gains traction throughout 2026, as we expand public payer access in early 2027, and then launch NEXLIZET in 2027. Our base business is stable and profitable, our balance sheet is strong, and we have financial flexibility to pursue additional portfolio expansion. We've built the foundation and are now positioned to drive sustained profitable growth." Q4 & F2025 FINANCIAL REVIEW The Company's Management's Discussion and Analysis and Consolidated Financial Statements for the three and twelve months ended December 31, 2025, are available at the Company’s website and at its pro SEDAR+ . Revenue Three months ended December 31, Year ended December 31, 2025 2024 2025 2024 Product sales Canada 11,637 11,694 42,385 42,572 United States 3,337 3,661 12,370 12,568 14,974 15,355 54,755 55,140 Royalty revenue 221 187 745 1,479 15,195 15,542 55,500 56,619 Revenue for fiscal 2025 decreased 2% to $55.5 million compared to $56.6 million in fiscal 2024. Excluding the impact of foreign exchange, revenue from marketed products increased 1%, with Vascepa growth offset, in part, by Clozaril regional competitive dynamics as noted in the Company's Q3 2025 reporting. Revenue for Q4 2025 decreased 2% to $15.2 million compared to $15.5 million in Q4 2024, primarily due to softer revenue in the U.S. business. Product sales – Canada 000's of CAD Three months ended December 31, Year ended December 31, 2025 2024 % change 2025 2024 % change Clozaril 9,637 9,712 (0.8) % 34,377 35,721 (3.8) % Vascepa 6,540 6,595 (0.8) % 24,609 22,550 9.1 % Other 55 6 228 60 16,232 16,313 (0.5) % 59,214 58,331 1.5 % For fiscal 2025, Canadian product sales in local currency increased 1.5%. Vascepa sales and unit volumes grew 9% and 23%, respectively, reflecting the Company's sales force changes and expanded provincial access, while Clozaril Canada sales declined 4% due to regional competitive dynamics. Canadian product sales for Q4 2025 decreased 0.5%. Product Sales – United States In the U.S. market, Clozaril revenue for fiscal 2025 decreased 1.6% compared to fiscal 2024, a considerable improvement over the prior four-year average annual decline of 6%. This reflects the success of the Company's specialty pharmacy program in offsetting patient attrition. Q4 2025 revenue decreased 9% year-over-year primarily due to timing of orders and shipments. Royalty revenues Royalty revenue for fiscal 2025 decreased 50% compared to fiscal 2024, as expected following the sale of the Company's Xenpozyme royalty interest in Q2 2024. The Company's remaining royalty interest in Obizur generated $0.22 million in Q4 2025 compared to $0.19 million in Q4 2024. Operating Expenses Three months ended December 31, Year ended December 31, 2025 2024 2025 2024 Cost of product sales 2,643 2,685 10,083 8,997 Selling and marketing 2,841 3,438 11,386 16,733 Medical, regulatory and patient support 1,634 1,539 5,708 5,663 General and administrative 2,366 2,323 8,700 8,578 9,484 9,985 35,877 39,971 Cost of product sales for fiscal 2025 increased due primarily to higher Vascepa sales volumes and were relatively flat in Q4 2025. HLS continues to demonstrate strong operational discipline. Operating expenses for fiscal 2025, comprising sales and marketing, G&A, and medical, regulatory, and patient support, decreased 17% compared to fiscal 2024. This reflects the Company's August 2024 discontinuation of co-promotional activities and ongoing cost optimization initiatives. For Q4 2025, operating expenses decreased 6% year-over-year. Adjusted EBITDA 1 Three months ended December 31, Year ended December 31, 2025 2024 2025 2024 Net loss for the period (1,335) (3,023) (12,430) (19,655) Stock-based compensation 11 423 1,912 1,617 Amortization and depreciation 5,463 5,434 21,817 22,717 Finance and related costs, net 1,702 2,295 7,391 10,293 Other costs (income) 517 343 1,378 (2,397) Income tax expense (recovery) (647) 85 (445) 4,073 Adjusted EBITDA 5,711 5,557 19,623 16,648 Adjusted EBITDA for fiscal 2025 increased 18% compared to fiscal 2024, driven by strong operational discipline and cost optimization initiatives, partially offset by foreign exchange fluctuations and the decline in royalty revenue. Adjusted EBITDA for Q4 2025 increased 3% year-over-year, reflecting continued operational efficiencies. For fiscal 2025, the direct brand contribution from Clozaril to Adjusted EBITDA was $26.9 million, while the direct brand contribution from Vascepa to Adjusted EBITDA improved to $1 million from negative $3.6 million in fiscal 2024. In Q4 2025, the direct brand contribution from Clozaril to Adjusted EBITDA was $7.7 million, while the direct brand contribution from Vascepa to Adjusted EBITDA was $0.3 million. Net Loss Fiscal 2025 net loss was ($12.4) million, or ($0.39) per share, compared to a net loss of ($19.7) million, or ($0.62) per share, in fiscal 2024. Q4 2025 net loss was ($1.3) million, or ($0.04) per share, compared to a net loss of ($3.0) million, or ($0.10) per share, in Q4 2024. Net loss improved in both periods of 2025 due in part to the previously noted factors that have positively impacted Adjusted EBITDA this year. Cash from Operations and Financial Position Cash generated from operations for fiscal 2025 was $17.1 million, up 114% compared to $8.0 million in fiscal 2024. For Q4 2025, cash from operations was $6.5 million, up 103% compared to $3.2 million in Q4 2024. In 2025, the Company strengthened its balance sheet through disciplined capital allocation. During fiscal 2025, HLS made debt principal repayments totaling $17.8 million, reducing total borrowings under the credit agreement to $50.0 million at December 31, 2025, compared to $67.4 million at December 31, 2024. Net debt decreased to $38.3 million at December 31, 2025, compared to $50.0 million at December 31, 2024. Under its Normal Course Issuer Bid, the Company purchased 519,366 shares at a cost of $1.8 million during fiscal 2025. Cash was $11.7 million at December 31, 2025, compared to $17.5 million at December 31, 2024. The decrease reflects the debt principal repayments and share buyback activity, offset in part by the significant increase in cash from operations. Q4 2025 CONFERENCE CALL HLS will hold a conference call today at 8:30 am Eastern Time to discuss its Q4 and fiscal 2025 financial results. The call will be hosted by Mr. Craig Millian, CEO, Mr. John Hanna, CFO and Mr. Brian Walsh, CCO. To view the slides that accompany management's discussion, please use the webcast link. CONFERENCE ID: 88550 DATE: Thursday, March 12, 2026 TIME: 8:30 a.m. ET WEBCAST LINK: TRADITIONAL DIAL-IN NUMBER: 1-888-699-1199 or 1-416-945-7677 RAPIDCONNECT: To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: TAPED REPLAY: 1-888-660-6345 or 1-289-819-1450 REPLAY CODE: 88550 # The taped replay will be available for seven days and the archived webcast will be available for 365 days. A link to the live audio webcast and replay of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at . ABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: 1 CAUTIONARY NOTE REGARDING NON-IFRS MEASURES This press release refers to certain non-IFRS measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of HLS's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of HLS's financial information reported under IFRS. HLS uses non-IFRS measures to provide investors with supplemental measures of its operating performance and thus highlight trends in its core business that may not otherwise be apparent when relying solely on IFRS financial measures. HLS also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. HLS's management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets and assess HLS's ability to meet its future debt service, capital expenditure and working capital requirements. In particular, management uses Adjusted EBITDA as a measure of HLS's performance. To reconcile net income (loss) for the period with Adjusted EBITDA, each of (i) "stock-based compensation", (ii) "amortization and depreciation", (iii) "finance and related costs, net", (iv) "other costs (income)", and (v) "income tax expense (recovery)" appearing in the Consolidated Statement of Net Income (Loss) are added to net income (loss) for the period to determine Adjusted EBITDA. Adjusted EBITDA does not have any standardized meaning prescribed by IFRS and is not necessarily comparable to similar measures presented by other companies. Adjusted EBITDA should not be considered in isolation or as a substitute for net income (loss) prepared in accordance with IFRS as issued by the IASB . FORWARD LOOKING INFORMATION This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities, expectations regarding financial performance, and the NCIB and ASPP. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 11, 2026, and Management's Discussion and Analysis dated March 11, 2026, both of which have been filed on SEDAR+ and can be accessed at . Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. HLS THERAPEUTICS INC. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION [in thousands of U.S. dollars] As at As at December 31, 2025 December 31, 2024 ASSETS Current Cash 11,723 17,456 Accounts receivable 7,862 7,454 Inventories 8,139 9,058 Income taxes recoverable -- 71 Other current assets 1,370 1,361 Total current assets 29,094 35,400 Property, plant and equipment 1,338 997 Intangible assets 105,626 122,122 Deferred tax asset 1,143 857 Other non-current assets 328 528 Total assets 137,529 159,904 LIABILITIES AND SHAREHOLDERS' EQUITY Current Accounts payable and accrued liabilities 10,438 8,709 Provisions 10,456 8,367 Debt and other liabilities 4,817 5,317 Income taxes payable 410 152 Total current liabilities 26,121 22,545 Debt and other liabilities 46,678 61,944 Deferred tax liability 3,060 4,074 Total liabilities 75,859 88,563 Shareholders' equity Share capital 256,338 260,595 Contributed surplus 16,164 15,136 Accumulated other comprehensive loss (6,680) (10,210) Deficit (204,152) (194,180) Total shareholders' equity 61,670 71,341 Total liabilities and shareholders' equity 137,529 159,904 HLS THERAPEUTICS INC. CONSOLIDATED STATEMENTS OF LOSS Unaudited [in thousands of U.S. dollars, except per share amounts] Three months ended December 31, Year ended December 31, 2025 2024 2025 2024 Revenue 15,195 15,542 55,500 56,619 Expenses Cost of product sales 2,643 2,685 10,083 8,997 Selling and marketing 2,841 3,438 11,386 16,733 Medical, regulatory and patient support 1,634 1,539 5,708 5,663 General and administrative 2,366 2,323 8,700 8,578 Stock-based compensation 11 423 1,912 1,617 Amortization and depreciation 5,463 5,434 21,817 22,717 Finance and related costs, net 1,702 2,295 7,391 10,293 Other costs (income) 517 343 1,378 (2,397) Loss before income taxes (1,982) (2,938) (12,875) (15,582) Income tax expense (recovery) (647) 85 (445) 4,073 Net loss for the period (1,335) (3,023) (12,430) (19,655) Net loss per share: Basic and diluted $(0.04) $(0.10) $(0.39) $(0.62) HLS THERAPEUTICS INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Unaudited [in thousands of U.S. dollars] Three months ended December 31, Year ended December 31, 2025 2024 2025 2024 Net loss for the period (1,355) (3,023) (12,430) (19,655) Item that may be reclassified subsequently to net loss Unrealized foreign currency translation adjustment 1,018 (5,194) 3,530 (7,372) Comprehensive loss for the period (317) (8,217) (8,900) (27,027) HLS THERAPEUTICS INC. CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY [in thousands of U.S. dollars] Share capital Contributed surplus Accumulated other comprehensive loss Deficit Total Balance, December 31, 2023 262,127 13,865 (2,838) (175,457) 97,697 Shares repurchased (1,532) -- -- 932 (600) Change in share purchase obligation -- 300 -- -- 300 Stock option expense -- 971 -- -- 971 Net loss for the year -- -- -- (19,655) (19,655) Unrealized foreign currency translation adjustment -- -- (7,372) -- (7,372) Balance, December 31, 2024 260,595 15,136 (10,210) (194,180) 71,341 Shares repurchased (4,257) -- -- 2,458 (1,799) Stock option expense -- 1,028 -- -- 1,028 Net loss for the year -- -- -- (12,430) (12,430) Unrealized foreign currency translation adjustment -- -- 3,530 -- 3,530 Balance, December 31, 2025 256,338 16,164 (6,680) (204,152) 61,670 HLS THERAPEUTICS INC. CONSOLIDATED STATEMENTS OF CASH FLOWS Unaudited [in thousands of U.S. dollars] Three months ended December 31, Year ended December 31, 2025 2024 2025 2024 OPERATING ACTIVITIES Net loss for the period (1,335) (3,023) (12,430) (19,655) Adjustments to reconcile net loss to cash provided by operating activities Stock-based compensation 11 423 1,912 1,617 Amortization and depreciation 5,463 5,434 21,817 22,717 Gain on royalty sale -- -- -- (3,381) Accreted interest expense 115 314 2,056 1,226 Foreign exchange 773 -- 341 -- Fair value adjustment on financial assets and liabilities -- 3 -- 526 Deferred income taxes (76) 59 (1,300) 3,812 Net change in non-cash working capital balances related to operations 2,240 (5) 4,734 1,141 Cash provided by operating activities 6,507 3,205 17,130 8,003 INVESTING ACTIVITIES Intangible asset acquisition -- -- (1,000) -- Other intangible additions (283) -- (498) -- Additions to property, plant and equipment (33) -- (205) (15) Proceeds from royalty sale -- -- -- 13,250 Payment of purchase consideration -- (13) -- (1,500) Cash provided by (used in) investing activities (316) (13) (1,703) 11,735 FINANCING ACTIVITIES Shares repurchased (7) -- (1,799) (600) Repayment of old credit agreement borrowing -- (2,510) (67,441) (21,043) New credit agreement borrowing -- -- 57,236 -- Repayment of new credit agreement borrowing (5,032) -- (7,550) -- Debt costs (168) -- (1,388) (1,191) Lease payments (161) (144) (614) (530) Cash used in financing activities (5,368) (2,654) (21,556) (23,364) Net increase (decrease) in cash during the period 823 538 (6,129) (3,626) Foreign currency translation 122 (622) 396 (870) Cash, beginning of period 10,778 17,540 17,456 21,952 Cash, end of period 11,723 17,456 11,723 17,456 SOURCE HLS Therapeutics Inc.

Drug ApprovalFinancial Statement

05 Mar 2026

·www.biospace.com

HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease

First-in-class, once-daily oral non-statin therapy now available by prescription across Canada Addresses a significant unmet need for over half a million Canadians who can not get to their LDL-C goal on statin-based therapy or who are statin intolerant Supported by the landmark CLEAR Outcomes trial demonstrating reduction in major adverse cardiovascular events in nearly 14,000 patients TORONTO , March 5, 2026 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, today announced the commercial launch of NILEMDO™ (bempedoic acid) in Canada. NILEMDO is now available by prescription nationally. HLS in-licensed the exclusive rights to NILEMDO and NEXLIZET® (bempedoic acid and ezetimibe) for the Canadian market from Esperion Therapeutics Inc. ("Esperion") (NASDAQ: ESPR) in May 2025. Health Canada approved NILEMDO in November 2025. NILEMDO is indicated to reduce LDL-C and the risk of major cardiovascular events in adults who require additional low-density lipoprotein cholesterol ("LDL-C") lowering due to an inability to reach target levels with currently available therapies or due to statin intolerance. Cardiovascular disease is the second leading cause of death in Canada, yet many high-risk patients still cannot achieve guideline-recommended LDL-C targets. 1 HLS estimates that more than half a million Canadians may benefit from NILEMDO. 2 "Despite considerable evidence and guideline recommendations, too many Canadians are still not reaching their LDL-C targets" said Dr. Lawrence Leiter, Professor of Medicine and Nutritional Sciences at the University of Toronto. "Bempedoic acid (NILEMDO) offers a new option for Canadian patients who cannot achieve their LDL-C goal or are intolerant to statins. We now have a well-tolerated, once-daily oral therapy that is supported by strong clinical evidence including the large CLEAR Outcomes trial, that provides clinicians and their patients with a new means of reducing cardiovascular risk." A NOVEL MECHANISM ADDRESSING A LARGE UNMET NEED NILEMDO provides a novel, oral pathway for LDL-C lowering while being less likely to cause muscle-related side effects that limit statin adherence for many patients. In clinical practice, physicians typically initiate therapy with a statin, then add ezetimibe if additional LDL-C lowering is needed. NILEMDO fits directly into this established treatment paradigm, providing a meaningful step-up option for patients who remain above their LDL-C target on combination therapy or who cannot tolerate adequate statin doses. NILEMDO can be used alone or in combination with other LDL-lowering agents, including statins, ezetimibe, and PCSK9 inhibitors. The approval of NILEMDO is supported by the CLEAR Outcomes trial, a landmark randomized, double-blind cardiovascular outcomes study in nearly 14,000 patients with high cardiovascular risk who were unable to take recommended statin therapy. The trial demonstrated that bempedoic acid significantly reduced the risk of major adverse cardiovascular events ("MACE"), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and coronary revascularization. 3 "With the launch of NILEMDO, Canadians who have been unable to reach their LDL-C targets now have a new oral treatment option supported by robust cardiovascular outcomes data," said Craig Millian, CEO of HLS Therapeutics. "NILEMDO strengthens our cardiovascular portfolio and, along with Vascepa®, positions HLS as a leader in bringing novel oral cardiovascular medicines to the Canadian market. Importantly, we believe this medicine will help more Canadians achieve their LDL-C goals and reduce their cardiovascular risk." Nilemdo has been submitted for reimbursement under private and public plans and is currently under review. HLS is expecting meaningful private payer coverage in Q2 and potential for public reimbursement in late 2026. LOOKING AHEAD: NEXLIZET HLS is also advancing its regulatory submission for NEXLIZET (bempedoic acid and ezetimibe), a once-daily combination pill that combines two complementary LDL-lowering mechanisms. NEXLIZET demonstrated approximately 38% LDL-C reduction in clinical trials. HLS is working with its partner Esperion Therapeutics, Inc. to respond to Health Canada's outstanding requirements as expeditiously as possible and anticipates a 2027 commercial launch. ABOUT NILEMDO (bempedoic acid) NILEMDO (bempedoic acid) is a once-daily oral medicine indicated in Canada to reduce LDL-C and the risk of major cardiovascular events in adults who require additional LDL-C lowering due to an inability to reach target levels with currently available therapies or due to statin intolerance. NILEMDO is approved and marketed globally, including in the United States (as NEXLETOL®) and in Europe, where it has been available since 2020. In Canada, NILEMDO will benefit from eight years of data protection starting from its November 17, 2025, approval date. This period, combined with existing and pending patents, provides market exclusivity for the drug extending until 2040. To view the full Nilemdo product monograph, please click here . ABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: FORWARD LOOKING INFORMATION This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities and expectations regarding financial performance. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 12, 2025, and Management's Discussion and Analysis dated November 12, 2025, both of which have been filed on SEDAR+ and can be accessed at . Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. REFERENCES Internal Company estimates SOURCE HLS Therapeutics Inc.

Drug ApprovalClinical ResultAHA

05 Mar 2026

·www.biospace.com

/C O R R E C T I O N -- HLS Therapeutics Inc./

In the news release, HLS Therapeutics Announces NILEMDO™ (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease, issued 05-Mar-2026 by HLS Therapeutics Inc. over PR Newswire, we are advised by the company that the original version contained incorrect information introduced by PR Newswire during transmission. The complete, corrected release follows, with additional details at the end: HLS Therapeutics Announces NILEMDO™ (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease First-in-class, once-daily oral non-statin therapy now available by prescription across Canada Addresses a significant unmet need for over half a million Canadians who can not get to their LDL-C goal on statin-based therapy or who are statin intolerant Supported by the landmark CLEAR Outcomes trial demonstrating reduction in major adverse cardiovascular events in nearly 14,000 patients TORONTO , March 5, 2026 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, today announced the commercial launch of NILEMDO™ (bempedoic acid) in Canada. NILEMDO is now available by prescription nationally. HLS in-licensed the exclusive rights to NILEMDO and NEXLIZET® (bempedoic acid and ezetimibe) for the Canadian market from Esperion Therapeutics Inc. ("Esperion") (NASDAQ: ESPR) in May 2025. Health Canada approved NILEMDO in November 2025. NILEMDO is indicated to reduce LDL-C and the risk of major cardiovascular events in adults who require additional low-density lipoprotein cholesterol ("LDL-C") lowering due to an inability to reach target levels with currently available therapies or due to statin intolerance. Cardiovascular disease is the second leading cause of death in Canada, yet many high-risk patients still cannot achieve guideline-recommended LDL-C targets. 1 HLS estimates that more than half a million Canadians may benefit from NILEMDO. 2 "Despite considerable evidence and guideline recommendations, too many Canadians are still not reaching their LDL-C targets" said Dr. Lawrence Leiter, Professor of Medicine and Nutritional Sciences at the University of Toronto. "Bempedoic acid (NILEMDO) offers a new option for Canadian patients who cannot achieve their LDL-C goal or are intolerant to statins. We now have a well-tolerated, once-daily oral therapy that is supported by strong clinical evidence including the large CLEAR Outcomes trial, that provides clinicians and their patients with a new means of reducing cardiovascular risk." A NOVEL MECHANISM ADDRESSING A LARGE UNMET NEED NILEMDO provides a novel, oral pathway for LDL-C lowering while being less likely to cause muscle-related side effects that limit statin adherence for many patients. In clinical practice, physicians typically initiate therapy with a statin, then add ezetimibe if additional LDL-C lowering is needed. NILEMDO fits directly into this established treatment paradigm, providing a meaningful step-up option for patients who remain above their LDL-C target on combination therapy or who cannot tolerate adequate statin doses. NILEMDO can be used alone or in combination with other LDL-lowering agents, including statins, ezetimibe, and PCSK9 inhibitors. The approval of NILEMDO is supported by the CLEAR Outcomes trial, a landmark randomized, double-blind cardiovascular outcomes study in nearly 14,000 patients with high cardiovascular risk who were unable to take recommended statin therapy. The trial demonstrated that bempedoic acid significantly reduced the risk of major adverse cardiovascular events ("MACE"), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and coronary revascularization. 3 "With the launch of NILEMDO, Canadians who have been unable to reach their LDL-C targets now have a new oral treatment option supported by robust cardiovascular outcomes data," said Craig Millian, CEO of HLS Therapeutics. "NILEMDO strengthens our cardiovascular portfolio and, along with Vascepa®, positions HLS as a leader in bringing novel oral cardiovascular medicines to the Canadian market. Importantly, we believe this medicine will help more Canadians achieve their LDL-C goals and reduce their cardiovascular risk." Nilemdo has been submitted for reimbursement under private and public plans and is currently under review. HLS is expecting meaningful private payer coverage in Q2 and potential for public reimbursement in late 2026. LOOKING AHEAD: NEXLIZET HLS is also advancing its regulatory submission for NEXLIZET (bempedoic acid and ezetimibe), a once-daily combination pill that combines two complementary LDL-lowering mechanisms. NEXLIZET demonstrated approximately 38% LDL-C reduction in clinical trials. HLS is working with its partner Esperion Therapeutics, Inc. to respond to Health Canada's outstanding requirements as expeditiously as possible and anticipates a 2027 commercial launch. ABOUT NILEMDO (bempedoic acid) NILEMDO (bempedoic acid) is a once-daily oral medicine indicated in Canada to reduce LDL-C and the risk of major cardiovascular events in adults who require additional LDL-C lowering due to an inability to reach target levels with currently available therapies or due to statin intolerance. NILEMDO is approved and marketed globally, including in the United States (as NEXLETOL®) and in Europe, where it has been available since 2020. In Canada, NILEMDO will benefit from eight years of data protection starting from its November 17, 2025, approval date. This period, combined with existing and pending patents, provides market exclusivity for the drug extending until 2040. To view the full Nilemdo product monograph, please click here . ABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: FORWARD LOOKING INFORMATION This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities and expectations regarding financial performance. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 12, 2025, and Management's Discussion and Analysis dated November 12, 2025, both of which have been filed on SEDAR+ and can be accessed at . Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. REFERENCES Internal Company estimates Correction:  An earlier version of this release incorrectly displayed the name of the product in the headline. The name was corrected from 'NILEMDOTM' to 'NILEMDO™' SOURCE HLS Therapeutics Inc.

Drug ApprovalAHA

100 Deals associated with Bempedoic acid

External Link

KEGG	Wiki	ATC	Drug Bank
D10691	Bempedoic acid	C10AX15	DB11936

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyper LDL cholesterolaemia	Canada	HLS Therapeutics, Inc.	05 Mar 2026
Hypercholesterolemia	Japan	大塚製薬株式会社	19 Sep 2025
Cardiovascular Diseases	United States	Esperion Therapeutics, Inc.	22 Mar 2024
Myocardial Infarction	United States	Esperion Therapeutics, Inc.	22 Mar 2024
Primary Hyperlipidemia	United States	Esperion Therapeutics, Inc.	22 Mar 2024
Dyslipidemias	European Union	Daiichi Sankyo Europe GmbH	01 Apr 2020
Dyslipidemias	Iceland	Daiichi Sankyo Europe GmbH	01 Apr 2020
Dyslipidemias	Liechtenstein	Daiichi Sankyo Europe GmbH	01 Apr 2020
Dyslipidemias	Norway	Daiichi Sankyo Europe GmbH	01 Apr 2020
Primary hypercholesterolemia	European Union	Daiichi Sankyo Europe GmbH	01 Apr 2020
Primary hypercholesterolemia	Iceland	Daiichi Sankyo Europe GmbH	01 Apr 2020
Primary hypercholesterolemia	Liechtenstein	Daiichi Sankyo Europe GmbH	01 Apr 2020
Primary hypercholesterolemia	Norway	Daiichi Sankyo Europe GmbH	01 Apr 2020
Atherosclerosis	United States	Esperion Therapeutics, Inc.	21 Feb 2020
Heterozygous familial hypercholesterolemia	United States	Esperion Therapeutics, Inc.	21 Feb 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hyperlipidemias	Phase 3	United Kingdom	Esperion Therapeutics, Inc.	20 Feb 2017
Cerebrovascular Disorders	Phase 3	United States	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Argentina	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Australia	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Austria	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Belgium	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Brazil	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Bulgaria	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Canada	Esperion Therapeutics, Inc.	22 Dec 2016
Cerebrovascular Disorders	Phase 3	Chile	Esperion Therapeutics, Inc.	22 Dec 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05687071 (CTgov)	Phase 3	Hyper LDL cholesterolaemia	130	ETC-1002	iayvbasshy = bynxyatmgz kgooyakppq (wxkstggysi, fsfbuvcejo - opagnfozry) View more	-	20 Feb 2026
NCT02993406 (CLEAR Outcomes, Pubmed \| Am J Cardiovasc Drugs)	Phase 3	Hypercholesterolemia	13,970	Bempedoic acid	pzeozkvrrs(bfiwzidifl) = gjnolwgfef pvkqsmspgp (qorefybwal )	Positive	20 Aug 2025
				Placebo	pzeozkvrrs(bfiwzidifl) = glzmudyojd pvkqsmspgp (qorefybwal )
NCT05683340 (CTgov)	Phase 3	Hyper LDL cholesterolaemia	96	Placebo	wlmxcrbnrb(cizsrvnoov) = lovtnlkekr vsntemsckn (qmzzdixccv, 1.901) View more	-	13 Mar 2025
NCT02993406 (CLEAR Outcomes, Pubmed \| J Am Heart Assoc)	Phase 3	Obesity	6,177	Bempedoic Acid 180 mg	vvscwgyzjl(syxjqqjgrc) = yjktgxngjg mienqeofuc (gdayhpxjgd, 0.76 [0.63 - 0.92]) View more	Positive	18 Feb 2025
				Placebo	-
NCT05683340 (Company_Website) Manual	Phase 3	Hypercholesterolemia	96	Bempedoic acid 180 mg	bgbxbvscqj(ctxlhgijnw) = kuzwtbgbfm hiacrrgdnz (gdwysuclom ) Met	Positive	20 May 2024
				Placebo	bgbxbvscqj(ctxlhgijnw) = nakoivztnf hiacrrgdnz (gdwysuclom ) Met
NCT04784442 (CTgov)	Phase 2	Hypercholesterolemia	188	Placebo	msabnyqvfz(xlosisirhj) = ravwbjiofw opfkchfmve (icsfjjhnsn, 2.117) View more	-	04 Mar 2024
NCT02993406 (CLEAR Outcomes, CTgov)	Phase 3	Cardiovascular Diseases \| Coronary Artery Disease \| Cerebrovascular Disorders ... View more	13,970	Bempedoic acid 180 mg tablet (Bempedoic Acid 180 mg)	fwxqtzcnbs = cuonerwkty kpajhibsck (zyuzzfbcjd, tynxrqptxu - nvxoijnhxh) View more	-	03 Jan 2024
				Matching placebo tablet (Placebo Comparator)	fwxqtzcnbs = uytfheycun kpajhibsck (zyuzzfbcjd, yqkkubaeiz - arrwdniqop) View more
NCT02993406 (CLEAR Outcomes, ENDO2023)	Phase 3	Cardiovascular Diseases \| Coronary Artery Disease \| Cerebrovascular Disorders ... View more	-	Bempedoic Acid	tevbxzjauq(dlvgocebuf) = yyylwegzsj fmypwmfsad (hkwbbfmegc )	Positive	05 Oct 2023
NCT02993406 (Pubmed \| JAMA)	Phase 3	-	4,206	Bempedoic Acid	ecoanogmmu(hholaqlywd): HR = 0.61 (95% CI, 0.39 - 0.98) View more	Positive	24 Jun 2023
				Placebo
NCT02178098 (CTgov)	Phase 2	Hypertension \| Hypercholesterolemia	143	Placebo	sakogkfdlo(pwzizspaer) = vjzgnkorgw sdkykroxmz (hfxolczuon, 2.133) View more	-	04 Apr 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bempedoic acid

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation